Therapeutic Development - The company is focused on developing next-generation therapeutics for cancer patients through its TMAb™ platform, which targets immunosuppressive signals in the tumor microenvironment[14]. - Solnerstotug, a conditionally active monoclonal antibody targeting VISTA, is currently in a Phase 1/2 trial with 60 patients dosed as of March 17, 2025[16]. - The company plans to initiate a Phase 2 trial of solnerstotug in Q1 2026, pending sufficient capital[21]. - The TMAb platform is designed to unlock previously undruggable immune targets for oncology applications[18]. - The company has paused development of preclinical product candidates SNS-102, SNS-103, and SNS-201 to focus resources on solnerstotug[17]. - The combination of solnerstotug with cemiplimab showed a 14% objective response rate and a 62% disease control rate among 21 evaluable PD-(L)1 resistant "hot" tumor patients[63]. - Solnerstotug has a greater than 600-fold selective binding affinity for active VISTA at low pH compared to physiological pH[34]. - The company aims to leverage unique tumor features, such as acidity, to design therapeutics that selectively activate within the tumor[19]. - No dose-limiting toxicities were reported for solnerstotug, with the majority of adverse events being Grade 1 or 2[21]. - The pharmacokinetic profile of solnerstotug supports once every three week dosing, demonstrating linear elimination kinetics and dose-proportional increases in exposure[63]. Clinical Trial Results - Clinical data from the trial showed a 14% objective response rate and a 62% disease control rate among 21 evaluable PD-(L)1 resistant "hot" tumor patients[21]. - In the Phase 1/2 clinical trial, 94 patients have been enrolled as of March 17, 2025, with 60 patients dosed in the Phase 1 dose expansion portion[59][62]. - SNS-101 demonstrated significant tumor growth inhibition of 77% when combined with anti-mPD-1 compared to the isotype control group, with a p-value of <0.0001[50]. - SNS-101 was observed to enhance anti-PD-1 response and increase tumor-infiltrating CD8 T cells in VISTA-KI mice[44]. - The combination of SNS-101 with anti-mPD-1 resulted in a 50% survival benefit compared to 12.5% in the anti-mPD-1 alone group[50]. - Solnerstotug was well tolerated, with no dose-limiting toxicities observed, and the majority of adverse events were Grade 1 or 2 in severity[63]. Financial Performance and Funding - The company has incurred significant losses every year since its inception and expects to continue incurring losses over the next several years, with no assurance of achieving profitability[195]. - The company will require substantial additional funding to meet its financial needs and pursue business objectives, with potential delays or reductions in product development if capital is not raised[197]. - The company has primarily financed operations through the sale of equity securities and may seek additional capital through various means, including public or private equity offerings and debt financings[199]. - The company incurred a net loss of $34.1 million for the year ended December 31, 2023, and an accumulated deficit of $262.1 million as of December 31, 2024[207]. - The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future[209]. - Plans to initiate a Phase 2 clinical trial of solnerstotug in the first quarter of 2026 are contingent upon the ability to raise sufficient additional capital[201]. - The company may need to significantly delay, scale back, or discontinue the development or commercialization of its product candidates if unable to raise additional capital[200]. Regulatory Environment - Regulatory approval processes require significant time and financial resources, with the FDA reviewing biologics through a Biologics License Application (BLA) that must demonstrate safety, purity, and potency[99][112]. - The FDA has a 60-day period to accept a BLA for filing, followed by a ten-month review period for standard applications and six months for priority reviews[115]. - The FDA requires compliance with cGMP regulations for manufacturing facilities before approving a BLA, ensuring consistent production within required specifications[116]. - Orphan drug designation can provide financial incentives such as grant funding opportunities, tax advantages, and user fee waivers, and grants exclusivity for seven years post-approval[118]. - Fast track designation is available for new biological product candidates intended to treat serious conditions, expediting the review process[119]. - Priority review is granted to products that significantly improve safety and effectiveness compared to existing therapies, directing additional resources to their evaluation[121]. - Accelerated approval may be granted if a product shows meaningful advantages over existing therapies and meets specific endpoint criteria[122]. - Breakthrough therapy designation offers intensive guidance from the FDA for products showing substantial improvement over current therapies[123]. - Post-marketing requirements include monitoring adverse experiences and compliance with promotion regulations, with potential penalties for non-compliance[127]. Market Competition - The company operates in a highly competitive market for immunotherapies, with substantial investments made in recent years[89]. - The company faces substantial competition from large pharmaceutical and biotechnology firms, as well as smaller companies forming collaborations to enhance their research and development capabilities[90]. - Competitors include major players like AstraZeneca, Bristol Myers Squibb, and Merck, which have greater financial resources and expertise in research and development[93][94]. - The company’s commercial opportunity may be diminished if competitors develop safer, more effective, or economically beneficial products[96]. - Mergers and acquisitions in the pharmaceutical sector may lead to increased resource concentration among competitors, intensifying competition[94]. Compliance and Legal Risks - Compliance with healthcare laws and regulations is resource-intensive and may divert management's attention from core business operations[138]. - Non-compliance with healthcare laws can result in significant penalties, including civil, criminal, and administrative actions, which could adversely affect business operations[139]. - The company may face challenges from ongoing legislative initiatives aimed at reducing healthcare costs, which could create uncertainty in the market[149]. - Changes in regulations could necessitate modifications to manufacturing arrangements, product labeling, or even lead to product recalls, impacting business operations[137]. - Non-compliance with foreign regulatory requirements may result in fines, product recalls, and other severe consequences[175]. Workforce and Restructuring - The company plans to reduce its workforce by approximately 46% as part of a restructuring plan, incurring costs of $0.7 million primarily for employee termination and severance payments[185]. - As of March 24, 2025, the company had 14 full-time employees and one part-time employee, maintaining a good relationship with its workforce[184]. Economic Factors - Economic downturns, inflation, and geopolitical events may adversely affect the company's business and financial performance[217]. - The Federal Reserve has raised interest rates multiple times in response to inflation concerns, which may increase economic uncertainty and affect financing conditions[219].

[Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress](index=1&type=section&id=Sensei%20Biotherapeutics%20Reports%20Full%20Year%202024%20Financial%20Results%20and%20Update%20on%20Clinical%20Progress) The company reports promising preliminary efficacy and safety data for solnerstotug in PD-(L)1 resistant tumors, with cash reserves projected into Q2 2026 - Preliminary efficacy data from the Phase 1/2 dose expansion cohort in PD-(L)1 resistant "hot" tumor patients show durable responses and tumor shrinkage[1](index=1&type=chunk) - Solnerstotug (formerly SNS-101) continues to demonstrate a favorable safety and tolerability profile[1](index=1&type=chunk) - The dose expansion cohort has reached its target enrollment, with full data expected by the end of 2025[1](index=1&type=chunk) - The company's cash reserves are projected to support operations into the second quarter of 2026[1](index=1&type=chunk) [Highlights and Milestones](index=1&type=section&id=Highlights%20and%20Milestones) The company achieved significant clinical and scientific milestones for solnerstotug, including positive preliminary efficacy data and completion of dose expansion enrollment [Solnerstotug (formerly SNS-101) Clinical Program](index=1&type=section&id=Solnerstotug%20(formerly%20SNS-101)) Solnerstotug is a conditionally active antibody designed to selectively target the VISTA immune checkpoint within the tumor microenvironment, currently evaluated in a Phase 1/2 trial as monotherapy and in combination with Libtayo® for advanced solid tumors - Solnerstotug is a conditionally active antibody designed to selectively target the VISTA immune checkpoint within the tumor microenvironment (TME)[4](index=4&type=chunk) - The company is conducting a Phase 1/2 clinical trial evaluating the safety and efficacy of solnerstotug as monotherapy and in combination with Libtayo® (cemiplimab)[5](index=5&type=chunk) [Preliminary Activity in PD-(L)1 Resistant 'Hot' Tumors](index=1&type=section&id=Preliminary%20Activity%20in%20PD-(L)1%20Resistant%20'Hot'%20Tumors) As of March 17, 2025, the combination of solnerstotug and cemiplimab demonstrated a **14% objective response rate (ORR)** and **62% disease control rate (DCR)** in 21 evaluable PD-(L)1 resistant "hot" tumor patients, significantly exceeding historical data with a favorable safety profile and no dose-limiting toxicities Preliminary Efficacy Data in PD-(L)1 Resistant 'Hot' Tumor Patients (As of March 17, 2025) | Metric | Result | | :--- | :--- | | **Objective Response Rate (ORR)** | 14% | | **Disease Control Rate (DCR)** | 62% | | **Complete Response (CR)** | 1 case (Merkel cell carcinoma) | | **Partial Response (PR)** | 2 cases (1 Merkel cell carcinoma, 1 MSI-H colorectal cancer) | - The observed **14% ORR** is nearly three times the historical PD-(L)1 re-challenge response rate (≤5%), indicating significant disease control in resistant tumors[5](index=5&type=chunk) - Solnerstotug continues to demonstrate good tolerability, with only **4 cases (7%) of Grade 1 cytokine release syndrome (CRS)** among 60 patients, all mild and manageable, and no dose-limiting toxicities observed[10](index=10&type=chunk) [Clinical Progress and Outlook](index=2&type=section&id=Clinical%20Progress%20and%20Outlook) The dose expansion cohort has completed its target enrollment of 60 patients, with full data anticipated by the end of 2025, as the company focuses on completing ongoing patient studies and finalizing a robust Phase 2 strategy - The dose expansion cohort has reached its target enrollment (**n=60**)[10](index=10&type=chunk) - Full expansion data are expected to be released by the end of 2025[10](index=10&type=chunk) - The company is focused on completing the dose expansion study for patients currently under investigation and finalizing a robust Phase 2 strategy[3](index=3&type=chunk) [Scientific and Clinical Visibility](index=2&type=section&id=Scientific%20and%20Clinical%20Visibility) The company enhanced its scientific and clinical visibility in 2024 through various academic conferences and publications, notably a peer-reviewed paper in Nature Communications detailing solnerstotug's mechanism of action - Spatial proteomic analysis of VISTA and PSGL-1 across various tumor types was presented at the SITC 2024 conference[10](index=10&type=chunk) - A peer-reviewed research paper describing solnerstotug's mechanism of action, selectively targeting the active form of VISTA within the tumor microenvironment, was published in Nature Communications in April 2024[10](index=10&type=chunk) [Corporate Updates](index=2&type=section&id=Corporate%20Updates) The company underwent organizational restructuring in Q4 2024 to streamline operations and made key leadership appointments [Organizational Restructuring and Appointments](index=2&type=section&id=Organizational%20Restructuring%20and%20Appointments) In Q4 2024, the company underwent organizational restructuring to streamline operations and focus resources on solnerstotug's clinical advancement, alongside appointing new finance and accounting leadership and a part-time Chief Medical Officer - In the fourth quarter of 2024, the company implemented organizational restructuring to streamline operations and concentrate resources on solnerstotug's clinical development[10](index=10&type=chunk) - Josiah Craver was appointed Senior Vice President of Finance, subsequently assuming the role of Chief Financial and Accounting Officer[10](index=10&type=chunk) - Ron Weitzman, M.D., F.A.C.P., was appointed as part-time Chief Medical Officer[10](index=10&type=chunk) [Year End 2024 Financial Results](index=2&type=section&id=Year%20End%202024%20Financial%20Results) The company reported a reduced net loss for 2024, with sufficient cash reserves to fund operations into the second quarter of 2026 [Financial Highlights](index=2&type=section&id=Financial%20Highlights) As of December 31, 2024, the company held **$41.3 million** in cash, cash equivalents, and marketable securities, projected to fund operations into Q2 2026, with R&D expenses at **$18.6 million** (flat year-over-year) and G&A expenses at **$13.0 million** (decreased year-over-year), resulting in a full-year net loss of **$30.2 million**, a reduction from the prior year 2024 Financial Performance Overview (Compared to 2023) | Financial Metric | December 31, 2024 (Millions USD) | December 31, 2023 (Millions USD) | Change (Millions USD) | | :--- | :--- | :--- | :--- | | **Cash, Cash Equivalents, and Marketable Securities** | $41.3 | $65.8 | Decrease $24.5 | | **Research & Development (R&D) Expenses** | $18.6 | $18.3 | Increase $0.3 | | **General & Administrative (G&A) Expenses** | $13.0 | $18.8 | Decrease $5.8 | | **Net Loss** | $30.2 | $34.1 | Decrease $3.9 | - The company projects its current cash balance is sufficient to support operations into the second quarter of 2026[7](index=7&type=chunk) [Financial Statements](index=3&type=section&id=Financial%20Statements) The financial statements detail a reduced net loss and decreased operating expenses for 2024, alongside changes in assets and liabilities [Condensed Statements of Operations](index=3&type=section&id=Condensed%20Statements%20of%20Operations) For fiscal year 2024, total operating expenses decreased to **$32.614 million** from **$37.064 million** in 2023, with net loss narrowing from **$34.101 million** in 2023 to **$30.157 million** in 2024, and net loss per share decreasing from **$1.22** to **$1.20** Condensed Statements of Operations (Amounts in thousands, except per share data) | | 2024 | 2023 | | :--- | :--- | :--- | | **Operating Expenses:** | | | | Research & Development Expenses | $18,627 | $18,299 | | General & Administrative Expenses | $13,036 | $18,765 | | Impairment of long-lived assets | $951 | $— | | **Total Operating Expenses** | **$32,614** | **$37,064** | | **Operating Loss** | **($32,614)** | **($37,064)** | | Total other income | $2,457 | $2,963 | | **Net Loss** | **($30,157)** | **($34,101)** | | **Net Loss Per Share (Basic and Diluted)** | **($1.20)** | **($1.22)** | [Selected Condensed Balance Sheet Data](index=4&type=section&id=Selected%20Condensed%20Balance%20Sheet%20Data) As of December 31, 2024, total assets were **$45.361 million**, total liabilities were **$6.975 million**, and total stockholders' equity was **$38.386 million**, with both total assets and stockholders' equity decreasing compared to year-end 2023 Selected Condensed Balance Sheet Data (Amounts in thousands) | | December 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $9,994 | $13,011 | | Marketable securities | $31,341 | $52,746 | | **Total assets** | **$45,361** | **$74,374** | | **Total liabilities** | **$6,975** | **$9,479** | | **Total stockholders' equity** | **$38,386** | **$64,895** | [Cautionary Note Regarding Forward-Looking Statements](index=4&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This press release contains forward-looking statements involving risks and uncertainties regarding product candidate development, potential therapeutic benefits, clinical trial timing, and cash flow projections, where actual results may differ materially from expectations - This press release contains forward-looking statements involving risks and uncertainties regarding product candidate development, potential therapeutic benefits, clinical trial timing, and cash flow projections. Actual results may differ materially from expectations[16](index=16&type=chunk)

Core Insights - Sensei Biotherapeutics reported promising preliminary efficacy data for solnerstotug in patients resistant to PD-(L)1 therapy, showing durable responses and tumor shrinkage [1][2] - The company achieved target enrollment in the dose expansion cohort and expects full data by the end of 2025 [1][9] - Sensei's cash position is projected to fund operations into the second quarter of 2026 [11] Clinical Development - Solnerstotug is designed to target the immune checkpoint VISTA, which is associated with poor survival rates in various cancers [3] - The ongoing Phase 1/2 clinical trial is evaluating solnerstotug as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® [4] - Preliminary data indicated a 14% overall response rate (ORR) and a 62% disease control rate (DCR) in evaluable PD-(L)1 resistant "hot" tumor patients [8] Safety Profile - Solnerstotug has shown a favorable safety profile, with no dose-limiting toxicities reported and most adverse events being Grade 1 or 2 [6] - Among 60 patients, only four (7%) experienced mild Grade 1 cytokine release syndrome [6] Financial Performance - As of December 31, 2024, the company reported cash, cash equivalents, and marketable securities totaling $41.3 million, down from $65.8 million in 2023 [11] - Research and development expenses increased slightly to $18.6 million in 2024 from $18.3 million in 2023, primarily due to clinical trial costs [12] - General and administrative expenses decreased to $13.0 million in 2024 from $18.8 million in 2023, attributed to lower external service costs [13] Corporate Updates - The company has made organizational changes to streamline operations and focus on advancing solnerstotug [16] - Key appointments include Josiah Craver as Senior Vice President of Finance and Ron Weitzman, M.D., as part-time Chief Medical Officer [16]

Core Insights - Sensei Biotherapeutics has reported initial clinical activity of solnerstotug in a PD-(L)1 resistant population, showing an overall response rate (ORR) of 14%, which is nearly three times higher than historical response rates for PD-(L)1 rechallenge [1][3][4] - The study included patients with various "hot" tumors and demonstrated durable responses, including a complete response in a Merkel Cell Carcinoma (MCC) patient and partial responses in other patients [1][6][13] - The company plans to initiate a Phase 2 study in Q1 2026, pending sufficient capital, with ongoing analyses to optimize patient selection and trial design [10] Company Overview - Sensei Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer, utilizing its TMAb™ platform to create conditionally active therapeutics [14] - The lead product candidate, solnerstotug, targets VISTA to restore T cell activity in tumors resistant to checkpoint inhibitors [14] Clinical Trial Details - The Phase 1 dose expansion trial is evaluating solnerstotug as a monotherapy and in combination with Libtayo (cemiplimab) across various tumor types, including both "hot" and "cold" tumors [4][6] - As of March 17, 2025, the trial has enrolled 60 patients, with 21 evaluable PD-(L)1 resistant "hot" tumor patients showing a 14% ORR and a 62% disease control rate (DCR) [5][6] Safety and Tolerability - Solnerstotug has been well tolerated, with no dose-limiting toxicities reported; the majority of adverse events (AEs) were Grade 1 or 2 in severity [7] - There were four cases (7%) of Grade 1 cytokine release syndrome, all mild and manageable [7] Treatment Landscape - Patients with PD-(L)1 resistant tumors face a poor prognosis, with a ≤5% likelihood of response to PD-(L)1 rechallenge, highlighting a significant unmet medical need [3][8] - Current treatment options for these patients are limited, often involving chemotherapy or experimental therapies [8] Future Directions - The company is preparing for the Phase 2 study, with plans to incorporate biomarker-based patient selection strategies based on ongoing trial results [10]

Core Viewpoint - Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [2]. - The recent upgrade for Sensei Biotherapeutics is driven by a 42.9% increase in the Zacks Consensus Estimate over the past three months, with expected earnings of -$1.17 per share for the fiscal year ending December 2024, representing a 4.1% change from the previous year [9]. Impact of Institutional Investors - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [5][6]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - The upgrade of Sensei Biotherapeutics to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [11].

Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025 [1] - Sensei's lead product candidate is solnerstotug, designed to block the VISTA checkpoint selectively in the tumor microenvironment [3] Company Overview - Sensei Biotherapeutics operates through its TMAb™ platform, which develops conditionally active therapeutics to target immunosuppressive signals in tumors [3] - The company's approach aims to activate T cells against tumors by selectively disabling immunosuppressive mechanisms [3] Event Details - John Celebi, President and CEO of Sensei, will present at the conference virtually at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website for approximately 90 days post-event [2]

Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target the tumor microenvironment, aiming to enhance T cell activity against tumors [3] Product Development - Sensei's lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in the low pH tumor microenvironment, which is crucial for T cell activation [3] Upcoming Events - John Celebi, President and CEO of Sensei Biotherapeutics, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days post-event [2]

Core Insights - Sensei Biotherapeutics is advancing its lead program, solnerstotug (SNS-101), which targets the immune checkpoint VISTA, with expectations for significant clinical data updates in 2025 [1][2][4] Company Overview - Sensei Biotherapeutics is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients, utilizing its TMAb™ platform to create conditionally active therapeutics [4][5] Product Development - Solnerstotug (SNS-101) is designed to selectively target VISTA within the tumor microenvironment, which is associated with low survival rates in various cancer types [3][4] - The company is conducting a multi-center Phase 1/2 clinical trial to evaluate solnerstotug's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® [4][5] Clinical Trial Progress - As of January 1, 2025, 45 patients have been enrolled in the dose expansion portion of the trial, with an expected total of approximately 60 patients by the end of Q1 2025 [5] - The company anticipates reporting data from evaluable patients in Q2 2025, including follow-up data from dose escalation cohorts [5] Financial Position - Sensei Biotherapeutics has a cash runway projected into the second quarter of 2026, allowing for the advancement of solnerstotug through the completion of the Phase 1 portion of the study [2][5]

Core Insights - Sensei Biotherapeutics is advancing the clinical development of SNS-101, with Phase 1/2 dose expansion clinical data expected in the first half of 2025 [1][5] - The company is undergoing organizational restructuring to focus resources on SNS-101, which includes a workforce reduction of approximately 46% [2][6] - The cash runway has been extended into the second quarter of 2026, with cash, cash equivalents, and marketable securities totaling $47.0 million as of September 30, 2024 [1][7] Clinical Development - SNS-101 is a conditionally active antibody targeting the immune checkpoint VISTA, which is associated with low survival rates in various cancer indications [3] - The Phase 1/2 clinical trial is evaluating SNS-101's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD1 inhibitor Libtayo® [4] - Patient enrollment in the dose expansion portion of the study is progressing, with approximately half of the study enrolled [5] Financial Performance - Research and Development (R&D) expenses for Q3 2024 were $4.6 million, an increase from $3.8 million in Q3 2023, primarily due to higher clinical trial costs [8] - General and Administrative (G&A) expenses decreased to $3.2 million in Q3 2024 from $3.9 million in Q3 2023, attributed to lower insurance premiums and outside services [9] - The net loss for Q3 2024 was $7.3 million, slightly higher than the $7.1 million loss in Q3 2023 [9][11] Corporate Updates - The company is closing its research site in Rockville, Maryland, as part of its restructuring efforts [6] - Josiah Craver was appointed as Senior Vice President, Finance, and later as the principal financial officer [6] - Sensei presented data on SNS-101 at various industry conferences, including PEGS Europe and the Society of Immunotherapy Cancer Annual Meeting [5]

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences. Conference and Presentation Details: PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditiona ...